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Oral Mucositis: the New Paradigms
Douglas E. Peterson, DMD, Ph.D and Rajesh V. Lalla, DDS, Ph.D, CCRP
Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental
Medicine & Neag Comprehensive Cancer Center, University of Connecticut Health Center, 263
Farmington Ave, Farmington CT, 06030-1605
Abstract
Purpose of review—Mucositis has long been viewed as an unavoidable consequence of high-
dose chemotherapy and/or radiation. Management has been directed to supportive care including
oral pain control, nutritional support, infection treatment and control of diarrhea. While these
interventions have been valuable for clinical management, they have not been collectively directed
to molecularly targeted prevention and treatment. This review addresses recent advances regarding
mucosal injury in cancer patients, with emphasis on symptom clusters, genetically-based tissue
susceptibility and risk prediction, imaging technology, and computational biology.
Recent findings—Modeling of symptom clusters in cancer patients continues to mature.
Although integration of mucositis into the paradigm is at an early stage, recent reports suggest that
important molecular and clinical insights will emerge in this regard. Initial studies of genetic-
based tissue risk are also providing a research basis that may lead to clinical risk prediction
models.
These advances are in part being engineered via new imaging and computational biology
technologies, drawing upon literature in non-mucositis systems. Just as the past decade has been
hallmarked by linkage of pathobiology with clinical expression of mucosal toxicity, the next
decade promises to identify new molecular interactions and risk prediction models based on novel
application of the analytic technologies.
Summary—Recent research has culminated in convergence of molecular pathobiology with
models of symptom clusters, genetic-based risk, and imaging and computational biology. The field
is poised to further delineate this paradigm, with the goal of development of molecularly targeted
drugs and devices for mucositis management.
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Introduction
Mucositis in oncology patients represents inflammation of the mucosa caused by high-dose
chemotherapy and/or head and neck radiation1, 2. The injury can affect oral and/or
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gastrointestinal mucosa, depending on the cancer treatment regimen being utilized. Over the
past 10 years the concept of alimentary tract mucositis has evolved as a unifying paradigm3,
4. Descriptions of the effect of molecularly targeted therapies (e.g., mTOR) on the
modeling, including oral mucositis 5 *, are now being reported.
Key clinical manifestations of oral mucositis include painful erythema and ulceration. The
painful component associated with moderate-severe oral mucositis can be sufficiently severe
so as to cause reduction of chemotherapy doses in subsequent multi-cycle regimens and
temporary or permanent interruption of radiation therapy6, 7. Patients with oral mucositis
are significantly more likely to experience severe pain and weight loss8. Severity of oral
mucositis has been correlated with compromised swallowing function in patients, resulting
in the requirement for feeding via a gastrostomy tube 6, 9 Multi-cycle dose modifications
have been associated with increased cancer recurrence and decreased survival rates10.
These and related sequelae can result in hospitalization which in turn can increase cost of
care. For example and depending on severity, oral mucositis has been associated with
increased costs of $1,700–$6,000 per affected patient receiving head and neck radiation11.
Gastrointestinal mucositis can also be a common, important clinical problem12 *. Hallmarks
of the lesion include abdominal pain, bloating, and diarrhea. Although supportive care
approaches can be efficacious, there is need to develop new approaches for customized
therapies analogous to the approach taken for prevention and control of nausea and emesis.
Fortunately, important new linkages are being established in the literature relative to
molecular causation that is either unique to the gastrointestinal component, or indicative of
potentially common causative pathways with those involved in the oral mucositis
trajectory13, 14 **, 15–16.
Oral and gastrointestinal mucositis continues to represent an important unmet clinical need.
There is only one United States Food and Drug Administration (FDA)-approved drug for
oral mucositis prevention. This drug, palifermin17, was approved for use in patients with
hematologic malignancies and who are undergoing high-dose chemotherapy without or with
radiation, followed by hematopoietic stem cell rescue. Thus, palifermin is approved for use
in an at-risk population, but one that represents a relatively small number of the total
patients who might otherwise benefit from such mucositis therapies. There are no FDA-
approved molecularly-targeted drugs to prevent gastrointestinal mucositis.
Thus, new paradigms are needed to comprehensively address the complex relationships
among pathobiologic mechanisms, risk for clinical expression, and response to preventive
and treatment interventions. Fortunately, the state-of-the-science has positioned the field to
achieve major milestones in this modeling over the next five-ten years.
Symptom clusters
The importance of the adverse impact of multiple toxicities of cancer therapy on the cancer
patient has become increasingly delineated over the past five years 18 **, 19, 20, 21 *, 22.
These observations have led to development of the concept of a “symptom burden” for a
given patient, in which both severity of the symptoms as well as the patient's perception of
impact of the symptoms is relevant19. In this modeling, the “whole” is indeed greater than
the “sum of the parts”. Even mild toxicities (e.g., World Health Organization Grade 2),
when occurring in combination, can produce a constellation of injury that can be highly
clinically significant. In addition to the clinical implications, such modeling creates
important implications with targeting reduction in Grade 2 toxicities in addition to the
traditionally-targeted moderate-severe Grade 3 and 4 adverse events.
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There are few reports of the role of oral and gastrointestinal mucositis on symptom clusters.
Symptom clustering research is a relatively new field, and integration with mucositis
modeling is in its early stages. Several important opportunities exist for study, including (i)
common molecular pathways; and (ii) impact of direct reduction of one toxicity via drug or
device on a secondary reduction of another toxicity. It will be important to consider key
research issues as defined Miaskowski et al. in 2007 (Table 1)18 **.
Genetically-based tissue susceptibility and risk prediction
For many decades it has been observed that different oral mucosal anatomic sites vary in
their risk for developing clinically significant oral mucositis. For example, high dose
chemotherapy often causes at least moderate mucositis of the buccal mucosa, floor-of-
mouth, lateral tongue and soft palate, whereas hard palate and attached gingiva are rarely
involved1. In addition, the classic modeling of uniform commonality among mechanisms for
injury across the alimentary tract mucosa are now being challenged by recently emergent
data, including a recent study by Logan et al.14 ** Although the definitive new paradigm is
not fully established, these new lines of research are providing insights as to why some
chemotherapy regimens are more frequently associated than other regimens with oral and
gastrointestinal site-specific mucositis. The recent studies may also offer insight into
mechanisms by which specific mucosal sites (e.g, conjunctival mucosa) do not typically
develop clinical mucositis while other sites (e.g, buccal mucosa) are often at high risk.
As an example of important recent work in this field, the German 5-FU Toxicity Study
Group examined genetic markers for toxicity related to 5-fluorouracil23 **. A significant
genetic association between a DPD splice site mutation (DYPD*2A) and mucositis was
observed. These results are consistent with the fact that DPD has been previously shown to
rapidly metabolize the majority of 5-fluorouracil that is administered. Of note is that the
DPD mutation resulting in DPD deficiency has been described as the major determinant of
5-FU-associated toxicity24.
This line of research links well with previous work by another group that studied
thymidylate synthase (TS), an enzyme that synthesizes nucleotides. Elevated TS expression
has been associated with enhanced survival among patients receiving 5-FU25. Reduced TS
expression in normal colonic mucosa prior to 5-FU administration has been associated with
higher incidence of diarrhea, stomatitis, dose reduction and treatment discontinuation
following infusion with 5-FU26. Polymorphisms in the TYMS gene promoter that encodes
TS are also associated with 5-FU toxicity in colorectal cancer patients27.
This modeling is setting the stage for potential identification of degree of relative risk of
patients developing oral and/or gastrointestinal mucositis. It provides a cogent basis for
envisioning a scenario in which genetic variations will be evaluated prior to the
determination of cancer therapy regimen in order to select treatments that will be tolerable
as well as effective28.
Imaging technology
Imaging technology has principally been utilized as a diagnostic tool to evaluate state of
health or disease of mucosa. For example, infrared thermography has demonstrated evidence
of increased vascularity in patients with mucositis, although the stage of the lesion (e.g.
erythema versus ulceration) may be an important confounder relative to signal detection29.
Orthogonal polarization spectroscopy has utilized polarized light and real-time video
imaging to measure microcirculatory velocity and white blood cell margination in relation to
acute inflammation30. Laser Raman Spectroscopy (RS) is based on use of inelastic
scattering of monochromatic light and has recently been demonstrated to reliably acquire the
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signal from the oral mucosa of patients in reproducible fashion across anatomic oral sites
and to determine if the RS signature of normal oral mucosa is reproducible among anatomic
oral sites and among subjects of different races and gender31. Confocal laser
endomicroscopy is a light microscopic technique that permits construction of a 3-
dimensional image based on visualization of mucosal histology32, 33, 34. A recent report of
sidestream dark-field video microscopy identified alterations in the oral mucosal
microvasculature circulation that could represent an important mechanism of early tissue
injury35. Narrow band imaging is an optical filter technology that can differentiate between
deep and shallow blood vessels, which could provide additional insight into mucosal-based
change secondary to cancer therapy36, 37.
A novel application of imaging technology was reported in 2008, in which video-capsule
endoscopy was utilized to visualize small intestinal mucosal changes secondary to
conditioning chemotherapy in autologous hematopoietic cell transplant patients38 *.
Mucosal edema, erosion and ulceration were observed. This innovative application of
existing imaging technology may well lead to new insights relative to the relationship
between tissue-based change and clinical symptoms.
The recent advances in imaging technology, including those described above, will likely
further enhance the understanding of tissue-based changes in form and function, and also
provide new opportunities for standardized assessment of mucosal injury in the research
setting.
Computational biology
Given the molecular complexity of oral and gastrointestinal mucositis, it is becoming
increasingly important to develop new computational strategies to identify the critical
molecular network hubs and downstream pathways involved in the pathogenesis of
mucositis. This type of conceptual framework has been utilized for other biologic systems
39 ** and is becoming increasingly relevant to mucosal injury research as well. A systems
biology approach can represent a powerful tool, if there is a robust population of molecular
data with which to conduct the computational modeling.
This is a relatively new frontier for studying mucosal injury in cancer. A limited number of
relatively recent publications exist. For example, Bowen et al. studied the early time course
of gene expression in a rat model of gastrointestinal mucositis40. At 1 hour post-
chemotherapy, early changes included mitogen-activated protein kinase, cell cycle
regulation and cytokine receptor signaling, while approximately 72 hours later there were
changes to the complement cascade. Sonis et al. characterized the relationship of expressed
genes from cRNA in peripheral blood samples from patients undergoing chemoradiation for
head and neck cancer Evaluation of relationships of specific genes, canonical pathways and
functional networks demonstrated strong concordance between oral mucositis pathogenic
mechanisms in relation to the genes, pathways and networks41. More recent work by van
Erp et al. has demonstrated that the risk for mucosal inflammation was increased in the
presence of G allele in CYP1A1 2455A/G in patients receiving single-agent sunitinib42 **.
There is also now the opportunity to consider the modeling in the context of molecular-
based identified of microflora that heretofore may not have been integrated into the
paradigm43 **.
These studies are contributing to the foundation on which comprehensive data analysis of
subjects at low, medium and high risk for oral and/or gastrointestinal injury can be studied.
This type of research may lead to new paradigms relative to risk prediction for mucositis in
the future.
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Conclusions
The evidence base for mucositis caused by cancer therapies continues to escalate in scope
and volume. The recent application of state-of-the-science imaging and computational
technologies from other research fields to the molecular and clinical study of oral and
gastrointestinal mucositis is particularly innovative. Based on evolution of clinical and
scientific knowledge from other toxicities (e.g., nausea and emesis), it seems probable that
the next decade of mucositis research will lead to novel opportunities to predict risk of
injury as well as incorporate customized preventive and treatment approaches. These
advances could mark a new era for management of mucositis caused by cancer therapies,
and thus comprehensively redefine the paradigm of the toxicity that has been observed in
cancer patients for over 60 years.
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Table 1
Critical considerations in symptom cluster research with oncology patients 18
Conceptual considerations
• Refinement of the definition of a symptom cluster
• Development of criteria to be used to evaluate the relationship between and among the symptoms that are specified within a cluster
• Use of the term “symptom cluster” to refer to the empiric or de novo identification of symptom clusters using an appropriate
statistical procedure (e.g., factor analysis, cluster analysis)
• Use of the term “patient subgroups” (not clusters of patients) to refer to groups of patients with different experiences with a specific
symptom cluster that are identified using the appropriate statistical procedure (e.g., cluster analysis, latent profile analysis)
• Determination of the best approaches to evaluate the underlying molecular mechanisms for symptom clusters
Considerations associated with the empiric or de novo identification of symptom clusters
• Comparison of the various statistical approaches to identify symptom clusters
• Comparison of the various methodological approaches to identify symptom clusters
– Use of symptom severity scores or symptom distress scores to create symptom clusters
– Number and types of symptoms on the symptom inventory
– Generic versus disease-specific symptom inventories
• Epidemiologic studies to identify symptom clusters de novo
– Studies within and across cancer diagnoses
– Studies within and across cancer treatments
– Studies within and across stages of disease
Considerations associated with the identification of patient subgroups based on their experiences with a specific symptom cluster
• Determination of the criteria to be used to include various symptoms with a specific symptom cluster
• Determination of the optimal approaches to measure a specific symptom cluster phenotype to insure the most valid and reliable
patient subgroups
– Use of symptom intensity, symptom distress, and/or symptom frequency measures to characterize a specific symptom
cluster phenotype
– Use of a single-item symptom inventory versus a number of symptom-specific questionnaires to characterize a specific
symptom cluster phenotype
• Determination of the optimal statistical approaches to identify subgroups of patients based on their experiences with a specific
symptom cluster
• Identification of the optimal methods to determine the phenotypic characteristics of patient subgroups with different experiences
with a specific symptom cluster
• Identification of the optimal methods to characterize the underlying molecular mechanisms that explain the patient subgroups with
different experiences with a specific symptom cluster
• Replication studies of patient subgroups with different experiences with a specific symptom cluster
• Determination of the most sensitive patient outcomes to distinguish among subgroups of patients based on differences in their
experiences with a specific symptom cluster
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